Marker Therapeutics, Inc. - Common Stock (MRKR)
1.7600
-0.0800 (-4.35%)
Marker Therapeutics Inc is a biopharmaceutical company focused on the development of innovative immunotherapy treatments for cancer
The company specializes in creating personalized T cell therapies designed to harness the body's immune system to target and eliminate tumors. By utilizing a unique approach that enhances T cell functionality, Marker Therapeutics aims to provide more effective treatment options for various types of malignancies, contributing to advancements in oncology and improving patient outcomes through precision medicine.
Previous Close | 1.840 |
---|---|
Open | 1.890 |
Bid | 1.760 |
Ask | 1.790 |
Day's Range | 1.700 - 1.920 |
52 Week Range | 1.350 - 5.990 |
Volume | 207,052 |
Market Cap | 15.71M |
PE Ratio (TTM) | -1.600 |
EPS (TTM) | -1.1 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 196,562 |
News & Press Releases

Via Benzinga · March 5, 2025

Via Benzinga · December 19, 2024

Via Benzinga · December 5, 2024

MRKR stock results show that Marker Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 14, 2024

Marker Therapeutics just reported results for the fourth quarter of 2023.
Via InvestorPlace · June 28, 2024

Marker Therapeutics, Inc. (NASDAQMRKR) shares are trading higher by 3.0% to $5.50 Tuesday morning.
Via Benzinga · July 11, 2023

Via Benzinga · June 5, 2024

Marker Therapeutics just reported results for the first quarter of 2024.
Via InvestorPlace · May 15, 2024

Marker Therapeutics Inc (NASDAQMRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.
Via Benzinga · January 8, 2024

Via Benzinga · December 29, 2023

Via Benzinga · December 11, 2023
Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 12/11
Marker Therapeutics, Inc. (NASDAQMRKR) is one of today’s top gainers. The company’s shares have moved 1.92% on the day to $2.65.
Via Investor Brand Network · December 11, 2023

Marker Therapeutics Inc (NASDAQMRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter
Via Benzinga · September 11, 2023

Gainers Crinetics Pharmaceuticals, Inc. (NASDAQCRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
Via Benzinga · September 11, 2023
Cranford, New Jersey--(Newsfile Corp. - August 17, 2023) - Marker Therapeutics (NASDAQMRKR) highlights...
Via Newsfile · August 17, 2023

It's time to start Wednesday with an overview of all the biggest pre-market stock movers traders need to know about this morning!
Via InvestorPlace · August 9, 2023

Gainers Yellow Corporation (NASDAQYELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.
Via Benzinga · July 31, 2023

Gainers Tupperware Brands Corporation (NYSETUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest.
Via Benzinga · July 24, 2023
Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 7/24
Marker Therapeutics, Inc. (NASDAQMRKR) is one of today’s top gainers. The company’s shares are currently up 18.53% on the day to $7.83.
Via Investor Brand Network · July 24, 2023

Gainers Mobilicom Limited (NASDAQMOB) shares jumped 81.3% to $2.7187 after the company announced it received a commercial scale purchase order from Teledyne-FLIR for the production of drones for the U.S. Department of Defense.
Via Benzinga · July 10, 2023

Marker Therapeutics, Inc. (NASDAQMRKR) shares are trading higher by 18.7% to $5.15 Monday morning after the company announced the European Medicines Agency granted MT-401 an
Via Benzinga · July 10, 2023